drugset / Trial / NCT00750802

A Sedation/Cognition/EEG Study Using AZD6280 and Comparator

NCT00750802

Phase 1 Completed 17 enrolled AstraZeneca
RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of the study is to determine the effects of AZD6280 compared to lorazepam on sleepiness, concentration and brain activity.

Timeline

Start
2008-09
Primary completion
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD6280 Small molecule 10 mg Oral
Subject AZD6280 Small molecule 40 mg Oral
Comparator Lorazepam Small molecule 2 mg Oral

Indications

No indication recorded.